kidney cancer

Biotech

Merck's HIF-2α med nabbed in Peloton buyout, keeps on delivering

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.
Amirah Al Idrus Sep 18, 2020 3:00am

Dana-Farber researchers spot early kidney cancer with blood test

Jun 22, 2020 11:00am

Why 'hot' kidney tumors don't respond to PD-1 blockers

May 29, 2020 11:00am

Merck backs up Peloton buyout with promising kidney cancer data

May 13, 2020 5:00pm

Could the anti-cancer gene p53 be a target in kidney cancer?

Dec 20, 2019 9:42am

X4 Pharma founder Renato Skerlj signs on as its R&D chief

Sep 18, 2019 12:04pm